The Dangers of Media Misreporting Medicines
It's a tricky balance. It's a good thing that the media report on medicines. But it can be a bad thing when the media get it wrong.
The media is alleged to have got it wrong last week in reporting a study in the Annals of Internal Medicine. The article, entitled "
Two days later, the BBC article was denounced by the World Health Organization in a follow up piece that appeared in the Annals of Internal Medicine. The WHO piece, entitled
The incident exposes some interesting issues. One is the role that the media can or should play in disseminating research. Annals of Internal Medicine is not read by the general public. The BBC News website is. In principle it is obviously a good thing that complex scientific information is made available to a wider public. This of course often requires some degree of rewriting, to make the complexities comprehensible to non-specialists. And that rewriting always carries some risk of misinterpretation. So there is a heavy duty on the media to ensure accuracy in that rewriting.
Another is how specialists should react when the media misinterpret scientific findings. In this case, the response was swift from the WHO. Within 48 hours of the BBC piece appearing, the Director of the HIV/AIDS Department and the Director of the Department of Essential Medicines and Health Products had their criticism of it online in the Annals of Internal Medicine. That was certainly fast. But it was obviously not enough, because insofar as there was a risk of public misunderstanding resulting from the BBC piece, very few of those misled citizens would be reading Annals. So six days later the WHO sent out a general press release to draw attention to its criticism of the BBC piece.
The nature of the reaction by specialists is as important as the speed. The press release focuses on the suggestion that the BBC piece was misleading. But in support, it attaches the WHO article from Annals - and this, to the non-specialist, appears at first glance to back up the assertion in the BBC piece: "The authors of the study caution that this may require a trade-off between drug efficacy and cost savings", says the WHO article. A closer reading makes clear that the WHO take on the Walensky piece is more nuanced. But unfortunately (to borrow a term from the WHO), the first impression is often what counts in the non-specialist world.
One more reflection. The BBC piece itself is not (despite the impression given by the WHO) a black-turned-to white perversion of the original research. It uses its interpretation (or perhaps misinterpretation - it is not for this columnist to judge) as the lead-in to a broader discussion of generic HIV treatment, featuring plenty of distinct views from HIV organisations - and even a quote from Dr Walenksy herself. Which is very much the role of the media. I, of course, have to declare an interest, in that I have earned my living for many years by writing for non-specialists about specialist subjects. I would not wish to minimise the importance of fastidious accuracy, and more particularly in matters of great significance, but I would not wish, either, to inhibit intelligent discussion among non-specialists of specialist topics, merely because a risk exists of misinterpretation.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025